Pharmala Biotech Holdings Inc. (CSE:MDMA)

Pharmala Biotech Holdings Income Statement

Financials in millions CAD. Fiscal year is September - August.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	May 31, 2025	Aug 31, 2024	Aug 31, 2023	Aug 31, 2022	Aug 31, 2021
Revenue	0.42	1.04	0.53	0.08	-
Revenue Growth (YoY)	-69.75%	94.60%	581.44%	-	-
Cost of Revenue	-0.13	0.15	0.08	0	-
Gross Profit	0.55	0.89	0.45	0.08	-
Selling, General & Admin	0.92	0.71	1.15	0.71	0.36
Research & Development	0.27	0.13	-0.17	-	-
Operating Expenses	2.44	1.46	1.12	0.96	0.58
Operating Income	-1.89	-0.58	-0.67	-0.88	-0.58
Other Non Operating Income (Expenses)	-0.1	-0.25	-0.11	-0.11	-0.06
EBT Excluding Unusual Items	-2	-0.82	-0.78	-0.99	-0.64
Other Unusual Items	-0.04	-	-	-	-3.13
Pretax Income	-2.04	-0.82	-0.78	-0.99	-3.76
Net Income	-2.04	-0.82	-0.78	-0.99	-3.76
Net Income to Common	-2.04	-0.82	-0.78	-0.99	-3.76
Shares Outstanding (Basic)	98	89	85	80	30
Shares Outstanding (Diluted)	98	89	85	80	30
Shares Change (YoY)	11.19%	4.79%	5.98%	163.82%	-
EPS (Basic)	-0.02	-0.01	-0.01	-0.01	-0.12
EPS (Diluted)	-0.02	-0.01	-0.01	-0.01	-0.12
Free Cash Flow	-0.75	-0.32	-0.34	-0.63	-0.26
Free Cash Flow Per Share	-0.01	-0.00	-0.00	-0.01	-0.01
Gross Margin	130.89%	85.72%	85.36%	97.07%	-
Operating Margin	-448.06%	-55.73%	-125.74%	-1127.69%	-
Profit Margin	-484.42%	-79.55%	-146.58%	-1262.43%	-
Free Cash Flow Margin	-178.88%	-31.04%	-63.84%	-804.87%	-
EBITDA	-1.89	-0.57	-0.67	-0.87	-0.58
EBITDA Margin	-	-55.15%	-125.42%	-	-
D&A For EBITDA	-0	0.01	0	0.01	0
EBIT	-1.89	-0.58	-0.67	-0.88	-0.58
EBIT Margin	-	-55.73%	-125.74%	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.